Ryan joined +ND Capital in our Woodside office in 2021.
Ryan is Senior Vice President Translational Medicine and Clinical Strategy at Asceneuron, a clinical-stage company with novel small molecules for the treatment of neurodegenerative diseases. Previously, he trained as a physician-scientist and developed novel approaches to identify the targets and triggers of neuroinflammatory diseases like multiple sclerosis and acute flaccid myelitis. Ryan has authored first author publications in top-tier journals including Nature Medicine and the Proceedings of the National Academy of Sciences, is a patent holder, and is a board-certified Neurologist. Ryan is passionate about scientific discoveries that can be transformed into innovative drug companies, so that patients with unmet needs benefit from the latest advances in research.
Ryan completed his MD at Stanford and his Neurology residency at the University of California San Francisco. Afterwards, he completed a post-doctoral fellowship in the UCSF Division of Neuroinflammation and Glial Cell Biology and a clinical fellowship in the UCSF Multiple Sclerosis and Neuroinflammation Center.